Aeterna Zentaris presents AEZS-131 data against tumor at AACR meeting Aeterna Zentaris Inc. Poster #3563 Entitled, An extremely selective Erk 1/2 inhibitor with in-vivo anti tumor potency , Irene Seipelt, Eckhard Guenther, Lars Blumenstein, Gilbert Mueller, Peter Schmidt, Babette Aicher, Michael Teifel and Matthias Gerlach . In in vivo pharmacokinetic studies, AEZS-131 demonstrated a favorable PK profile. Anti-tumor activity was studied in in vivo mouse xenograft experiments utilizing the HCT-116 cancer of the colon model. AEZS-131 significantly inhibited tumor growth and was well tolerated at daily doses up to 120 mg/kg.Race has been demonstrated to be a significant independent risk factor in the clinical span of many diseases, including breast cancer and lung malignancy. Its role is complicated and may affect tumor behavior through genetic factors directly, lack of usage of health care, and treatment patterns. Few studies have examined the impact of race on patient care by examining specific physician-patient interactions. Moreover, few research have characterized treatment differences in Hispanic, Middle Eastern, and Asian ladies. Henry M. Kuerer, M.D., Ph.D., from the University of Texas M. D. Anderson Tumor Center and his co-workers reviewed data from 1004 patients with primary breast cancer treated with mastectomy.